Table 3 Number of Months of Overall Survival That Physicians Were Willing to Trade In Return for an Improvement in Other Attributes
From: Physician preferences for non-metastatic castration-resistant prostate cancer treatment
All Physicians | Urologists | Oncologists | ||||
|---|---|---|---|---|---|---|
Reduction, months | 95% CI | Reduction, months | 95% CI | Reduction, months | 95% CI | |
Time to pain progression | ||||||
Delay progression from 3 to 12 months | 3.0 | (1.6, 4.7) | 4.1 | (1.8, 7.0) | 1.5 | (−0.4, 3.8) |
Delay progression from 6 to 12 months | 2.1 | (0.8, 3.6) | 3.7 | (1.6, 6.6) | 0.6 | (−1.2, 2.6) |
Delay progression from 3 to 6 months | 0.9 | (− 0.5, 2.3) | 0.3 | (−1.8, 2.5) | 0.8 | (−1.1, 3.1) |
Fatigue | ||||||
Severe to none | 7.5 | (5.5, 10.1) | 10.6a | (7.0, 15.9) | 6.2 | (3.8, 10.4) |
Severe to mild-to-moderate | 6.6 | (4.9, 9.1) | 9.2a | (6.3, 13.9) | 5.7 | (3.3, 9.9) |
Mild-to-moderate to none | 0.8 | (−0.6, 2.3) | 1.4 | (−1.2, 3.8) | 0.5 | (− 1.5, 2.4) |
Skin rash | ||||||
Severe to none | 4.0 | (2.3, 6.0) | 7.0 | (4.3, 11.0) | 1.2 | (−1.1, 3.9) |
Severe to mild-to-moderate | 3.0 | (1.7, 4.7) | 6.0 | (3.5, 9.6) | 0.7 | (−1.2, 2.8) |
Mild-to-moderate to none | 0.9 | (−0.6, 2.5) | 1.0 | (−1.3, 3.7) | 0.5 | (−1.5, 2.7) |
Cognitive problems | ||||||
Severe to none | 11.6a | (8.9, 15.4) | 14.5a | (10.2, 21.2) | 10.5a | (6.7, 17.5) |
Severe to mild-to-moderate | 9.1a | (6.9, 12.1) | 12.2a | (8.8, 18.0) | 7.3 | (4.3, 12.5) |
Mild-to-moderate to none | 2.5 | (1.0, 4.2) | 2.2 | (−0.1, 4.8) | 3.2 | (0.9, 6.5) |
Serious fall | ||||||
8% to none | 5.2 | (2.9, 7.9) | 4.3 | (1.2, 8.2) | 6.4 | (2.7, 12.1) |
8 to 5% | 2.9 | (1.0, 5.1) | 2.4 | (−0.5, 5.9) | 3.4 | (0.7, 7.4) |
5% to none | 2.3 | (0.4, 4.4) | 1.8 | (−1.0, 5.1) | 3.0 | (0.2, 6.6) |
Serious fracture | ||||||
8% to none | 9.2a | (6.4, 12.7) | 7.7 | (3.7, 12.7) | 10.3a | (5.9, 17.7) |
8 to 5% | 3.9 | (1.8, 6.3) | 3.7 | (0.3, 7.4) | 4.6 | (1.5, 9.0) |
5% to none | 5.3 | (3.1, 7.8) | 4.0 | (0.7, 7.7) | 5.7 | (2.7, 10.5) |